治疗对胰腺导管腺癌（PDAC）外周血免疫细胞谱的影响。
The Effects of Treatment on Peripheral Blood Immune Cell Profile in Pancreatic Ductal Adenocarcinoma (PDAC).
机构信息
Hematology, Oncology and Transfusion Medicine Center, Vilnius University Hospital Santaros Klinikos, Vilnius, Lithuania;
Institute of Clinical Medicine, Faculty of Medicine, Vilnius University, Vilnius, Lithuania.
出版信息
Anticancer Res. 2022 Jun;42(6):3067-3073. doi: 10.21873/anticanres.15794.
BACKGROUND/AIM: This study evaluated whether circulating lymphocytes, assessed by flow cytometry, is a prognostic biomarker in pancreatic ductal adenocarcinoma (PDAC).
PATIENTS AND METHODS
We studied T cell subsets in blood samples from a cohort of 41 patients diagnosed with PDAC. Patients underwent surgery of the primary site and adjuvant chemotherapy or were treated with 1 line chemotherapy (mFOLFIRINOX regimen or gemcitabine alone). The changes in T cell subpopulations during treatment were evaluated at the initial diagnosis before surgery, and after 2 and 4 months. Friedman test was used for statistical analysis.
RESULTS
A decline in CD19+ B lymphocytes, natural killer (NK) cells CD3-CD56+CD16+, and T regulatory cells CD4+FOXP3+ during treatment was observed. NKT-like cells CD3+CD56+ and cytotoxic T cells CD3+CD8+ tended to increase after two months and decrease after that.
CONCLUSION
Statistically significant changes in lymphocyte counts in peripheral blood were detected in patients with PDAC during treatment.
背景/目的：本研究旨在评估通过流式细胞术评估的循环淋巴细胞是否是胰腺导管腺癌（PDAC）的预后生物标志物。
患者和方法
我们研究了来自 41 名 PDAC 患者队列的血液样本中的 T 细胞亚群。患者接受了原发部位的手术和辅助化疗，或接受了一线化疗（mFOLFIRINOX 方案或吉西他滨单药治疗）。在初始诊断时（手术前）以及治疗后 2 个月和 4 个月评估 T 细胞亚群的变化。采用 Friedman 检验进行统计学分析。
结果
在治疗过程中观察到 CD19+B 淋巴细胞、自然杀伤（NK）细胞 CD3-CD56+CD16+和 T 调节细胞 CD4+FOXP3+减少。NKT 样细胞 CD3+CD56+和细胞毒性 T 细胞 CD3+CD8+在两个月后趋于增加，之后减少。
结论
在 PDAC 患者治疗期间，外周血淋巴细胞计数发生了统计学上显著的变化。
Zotero 插件